Form 4: Talphera Director Mark Wan Receives Equity Grant

Talphera Director Mark Wan was granted 4,267 restricted stock units and options for 25,600 shares of common stock.

Summary

• Director Mark A. Wan acquired 4,267 restricted stock units (RSUs) and options to purchase 25,600 shares of Talphera, Inc. common stock.
• The grant date for both the RSUs and stock options was October 23, 2025.
• Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
• The 4,267 restricted stock units are scheduled to vest 100% on the first anniversary of the grant date, contingent upon Mr. Wan's continuous service to the company.
• The 25,600 stock options have an exercise price of $1.14 per share and are also scheduled to vest 100% on the one-year anniversary of the grant date, subject to continuous service.
• Following these transactions, Mark Wan directly beneficially owns 8,859 shares of common stock and 25,600 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of equity to a director is generally a positive sign of alignment between management and shareholder interests, incentivizing long-term performance. This is a routine compensation event rather than a performance report.

Positives

• Director Mark A. Wan received a significant equity grant, which aligns his financial interests with those of the company's shareholders.
• The grants are subject to a one-year vesting period, incentivizing long-term commitment and performance from the director.

Risks

• The restricted stock units and stock options are subject to forfeiture if Director Mark A. Wan's continuous service to the company is not maintained until the vesting date.

Future Outlook

The grants are subject to future vesting on the one-year anniversary of the grant date (October 23, 2026), contingent on continuous service, indicating an expectation of continued employment and performance from the director.

Industry Context

Equity grants to directors are a standard practice in publicly traded companies, particularly in growth-oriented sectors, to attract and retain talent and align the interests of key personnel with those of shareholders.

Comparison to Industry Standards

• The structure of equity compensation, including restricted stock units and stock options with vesting schedules, is a common practice across publicly traded companies, especially in sectors like biotechnology or pharmaceuticals (assuming Talphera's industry).
• The specific amounts granted would typically be benchmarked against peer companies of similar market capitalization, stage of development, and executive compensation policies, though such comparative data is not provided in this filing.

Stakeholder Impact

• Shareholders: The equity grant further aligns the financial interests of Director Mark A. Wan with those of the shareholders, potentially fostering decisions that enhance long-term shareholder value.

Next Steps

• Vesting of 4,267 restricted stock units on October 23, 2026, subject to Director Mark A. Wan's continuous service to the company.
• Vesting of 25,600 stock options on October 23, 2026, subject to Director Mark A. Wan's continuous service to the company.

Key Dates

Recommendation

This filing reports a routine equity grant to an existing director, which is a standard compensation practice designed to align management's interests with shareholders through performance-based vesting. It does not contain information significant enough to warrant a change in investment recommendation based solely on this disclosure.

Keywords

Talphera, TLPH, Mark Wan, Director, Insider Transaction, Form 4, Restricted Stock Units, Stock Options, Equity Grant, Executive Compensation